Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Optimization of Radiolabeling of a [ 90 Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell TransplantationCancers, 2023-07, Vol.15 (14), p.3660 [Peer Reviewed Journal]2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2023 by the authors. 2023 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers15143660 ;PMID: 37509321Full text available |
|
2 |
Material Type: Article
|
Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate CancerCancers, 2021-07, Vol.13 (14), p.3607 [Peer Reviewed Journal]2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 by the authors. 2021 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers13143607 ;PMID: 34298822Full text available |
|
3 |
Material Type: Article
|
Personalized [177Lu]Lutetium-PSMA Therapy for Patients with Pre-Treated Castration-Resistant Prostate Cancer: A Single Institution Experience from a Comprehensive Cancer CentreCancers, 2023-06, Vol.15 (12), p.3216 [Peer Reviewed Journal]COPYRIGHT 2023 MDPI AG ;2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2023 by the authors. 2023 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers15123216 ;PMID: 37370826Full text available |
|
4 |
Material Type: Article
|
Optimization of Radiolabeling of a [[sup.90]Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell TransplantationCancers, 2023-07, Vol.15 (14) [Peer Reviewed Journal]COPYRIGHT 2023 MDPI AG ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers15143660Full text available |